NCT03718039View on ClinicalTrials.gov

Phase 2 Bunionectomy HTX-011 Administration Study

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

March 11, 2019

Conditions
Postoperative Pain
Interventions
DRUG

HTX-011

HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.

DEVICE

Luer Lock applicator

Applicator for instillation.

DEVICE

Vial access device

Device for withdrawal of drug product.

DRUG

aprepitant

Aprepitant, three single doses of aprepitant will be administered orally.

Trial Locations (1)

78229

Endeavor Clinical Trials, LLC, San Antonio

Sponsors

Lead Sponsor

Heron Therapeutics
All Listed Sponsors
lead

Heron Therapeutics

INDUSTRY